<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.91015</article-id><article-id pub-id-type="publisher-id">ACM-28637</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190100000_97593247.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  启动子甲基化通过调节RAGE基因表达影响UC风险
  Promoter Methylation Alters the UC Risk by Regulating RAGE Expression
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>玉兰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>守泉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>月清</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>振演</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>家丰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>广东医科大学附属医院干细胞研发与临床转化中心，广东 湛江</addr-line></aff><aff id="aff2"><addr-line>广东医科大学附属医院临床医学研究中心，广东 湛江</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>88</fpage><lpage>95</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    末端糖基化终末产物受体基因(RAGE)被证实在多种炎症相关疾病中发挥重要的信号传导作用。最近我们在溃疡性结肠炎(UC)组织样本中发现在RAGE基因启动子区存在一个富含CpG的区域甲基化存在个体差异现象。启动子区高甲基化可能会影响基因的转录过程，因此本研究拟通过病例对照探索RAGE基因启动子区甲基化对其转录水平的影响极其甲基化与UC风险的相关性。研究发现启动子区甲基化程度与转录水平密切相关，该区域可能是调控RAGE基因转录的关键部位。我们的研究为进一步理解UC病变机理开辟新的切入点，同时为UC个性化风险精准预测提供理论基础。
    Receptor for advanced glycation end products (RAGE) has been shown to play an important role in signal transduction in a variety of inflammation-related diseases. Recently, we found an individual difference of methylation in a CpG-island located in the promoter region of RAGE gene. It has been proved that hypermethylation of promoter region may affect the transcription process of genes. Therefore, this study intends to explore the influence of methylation in promoter region of RAGE gene on its transcription level and the correlation between methylation and UC risk through a case control study. Studies have found that the methylation level of RAGE promoter region is closely related to its transcription level, and the methylation status of RAGE promoter region may be play an important role in regulating the transcription of RAGE genes. Our research opens up a new entry point for further understanding the pathogenesis of UC, and provides a theoretical basis for accurate prediction of personalized UC risk. 
  
 
</p></abstract><kwd-group><kwd>末端糖基化终末产物受体，溃疡性结肠炎，甲基化，转录, RAGE</kwd><kwd> UC</kwd><kwd> Methylation</kwd><kwd> Transcription</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>启动子甲基化通过调节RAGE基因表达影响UC风险<sup> </sup></title><p>周玉兰<sup>1</sup>，闫守泉<sup>2</sup>，蔡月清<sup>2</sup>，苏振演<sup>2</sup>，王家丰<sup>2*</sup></p><p><sup>1</sup>广东医科大学附属医院临床医学研究中心，广东 湛江</p><p><sup>2</sup>广东医科大学附属医院干细胞研发与临床转化中心，广东 湛江</p><disp-formula id="hanspub.28637-formula46"><graphic xlink:href="//html.hanspub.org/file/15-1570795x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年1月2日；录用日期：2019年1月18日；发布日期：2019年1月25日</p><disp-formula id="hanspub.28637-formula47"><graphic xlink:href="//html.hanspub.org/file/15-1570795x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>末端糖基化终末产物受体基因(RAGE)被证实在多种炎症相关疾病中发挥重要的信号传导作用。最近我们在溃疡性结肠炎(UC)组织样本中发现在RAGE基因启动子区存在一个富含CpG的区域甲基化存在个体差异现象。启动子区高甲基化可能会影响基因的转录过程，因此本研究拟通过病例对照探索RAGE基因启动子区甲基化对其转录水平的影响极其甲基化与UC风险的相关性。研究发现启动子区甲基化程度与转录水平密切相关，该区域可能是调控RAGE基因转录的关键部位。我们的研究为进一步理解UC病变机理开辟新的切入点，同时为UC个性化风险精准预测提供理论基础。</p><p>关键词 :末端糖基化终末产物受体，溃疡性结肠炎，甲基化，转录</p><disp-formula id="hanspub.28637-formula48"><graphic xlink:href="//html.hanspub.org/file/15-1570795x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/15-1570795x8_hanspub.png" /> <img src="//html.hanspub.org/file/15-1570795x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>溃疡性结肠炎(Ulcerative colitis, UC)是炎症性肠病(Inflammatory Bowel Disease, IBD)的一种。目前认为主要的病因是遗传因素以及环境因素导致的肠道免疫反应紊乱的结果 [<xref ref-type="bibr" rid="hanspub.28637-ref1">1</xref>] 。UC患者长期持续的炎症反应被认为有进一步癌变的风险 [<xref ref-type="bibr" rid="hanspub.28637-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref3">3</xref>] 。罹患UC达到20年的患者其结直肠癌的风险增加5%~10%，罹患UC大于30年则该风险增加到10%~30% [<xref ref-type="bibr" rid="hanspub.28637-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref5">5</xref>] 。</p><p>UC最主要的表现特征为慢性非特异性炎症反应。末端糖基化终末产物受体(receptor for advanced glycation end products, RAGE)是免疫球蛋白细胞表面分子超家族的一员。它是一个多配体的受体蛋白，可以与钙粒蛋白家族成员(例如S100A12和S100B)，高迁移率族蛋白B1 (HMGB1)，末端糖基化终末产物(AGE)以及β样淀粉肽(Aβ)等配体相互识别并引起一系列的细胞内信号传递过程最终传递并放大细胞炎症信号 [<xref ref-type="bibr" rid="hanspub.28637-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref7">7</xref>] 。RAGE被报道与多种炎症相关病变(例如糖尿病，关节炎，神经退行性疾病甚至癌变等)密切相关 [<xref ref-type="bibr" rid="hanspub.28637-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref11">11</xref>] 。通常RAGE主要在肺部表达而在肠道上皮组织中表达量比较低。但是在炎症过程中其表达量在内皮细胞，上皮细胞以及淋巴细胞中均呈现显著上调。动物模型中发现敲除RAGE基因后的小鼠可以来先天性免疫系统保护小鼠抵抗脓毒症。同时给与抗RAGE抗体干预动物模型发现大大减少多菌性脓毒症的盲肠结扎穿刺模型的致死率 [<xref ref-type="bibr" rid="hanspub.28637-ref8">8</xref>] 。近期研究表明在炎症性肠病(IBD)患者的肠道上皮组织中RAGE显著上调表达 [<xref ref-type="bibr" rid="hanspub.28637-ref12">12</xref>] ，而且RAGE抗体在小鼠IBD模型中可以显著减弱结肠炎症 [<xref ref-type="bibr" rid="hanspub.28637-ref13">13</xref>] 。总之，这些发现提示RAGE基因可能在调节IBD过程的炎症反应中具有重要的作用，这就使得其成为IBD潜在的风险生物标记。</p><p>研究发现DNA的甲基化可能会影响基因的表达和活性，越来越多的研究表明启动子区甲基化与基因表达活性存在反向相互作用机制 [<xref ref-type="bibr" rid="hanspub.28637-ref14">14</xref>] - [<xref ref-type="bibr" rid="hanspub.28637-ref21">21</xref>] 。研究发现在人类基因组中高达3%~6%的胞嘧啶存在甲基化现象，甲基化成为影响基因表达的重要因素 [<xref ref-type="bibr" rid="hanspub.28637-ref21">21</xref>] 。目前很多研究表明肿瘤抑制基因启动子区域内CpG岛异常甲基化导致多种肿瘤发生 [<xref ref-type="bibr" rid="hanspub.28637-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref23">23</xref>] 。RUNX3，MINT1和COX-2的启动子甲基化也被证实是UC患者结肠直肠异型增生的生物标志物 [<xref ref-type="bibr" rid="hanspub.28637-ref24">24</xref>] 。</p><p>虽然研究证实RAGE基因与UC的炎症反应过程密切相关 [<xref ref-type="bibr" rid="hanspub.28637-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref13">13</xref>] 。我们前期实验发现RAGE基因中的一个多态性位点(G82S)和UC风险直接密切相关 [<xref ref-type="bibr" rid="hanspub.28637-ref25">25</xref>] 。但是目前为止，鲜有研究报道RAGE基因启动子区甲基化和UC风险的相关性。我们最近研究发现在RAGE基因启动子区存在一个富含CpG的区域存在个体甲基化差异现象。本研究拟探索RAGE基因启动子区甲基化与其转录水平的关系并分析其与UC风险的相关性。</p></sec><sec id="s4"><title>2. 材料与方法</title><p>实验样本收集与DNA处理</p><p>在广东医科大学附属医院消化科诊断为UC住院病例，收集通过肠镜检查用活检钳取结肠组织样本共计60例(32例男性，28例女性)；UC的诊断标准采用常规的临床、内镜、组织学标准诊断确定为UC活动期患者，同时排除其他炎性疾病。另外在广东医科大学附属医院体检中心收集健康体检人员肠镜检查病例结肠组织样本60例(36例男性，24例女性)，健康对照组要求无肠炎症状，无恶性史，无IBD个人或家族病史。UC病例与健康对照个体民族相互匹配，年龄无显著差异。所有参与提供样本的病人全部签署知情同意书，并且由广东医科大学附属医院伦理委员会审批通过。</p><p>利用组织DNA提取试剂盒(Qiangen德国)提取结肠组织样本的基因组DNA。然后根据使用说明利用亚硫酸盐试剂盒(EpiTect Bisulfite Kit, Qiagen, Germany)处理基因组DNA，将所有未甲基化的胞嘧啶全部转化为尿嘧啶，而被甲基化的胞嘧啶将会被保留。</p><p>甲基化检测</p><p>利用甲基化在线预测软件(MethPrimer, PUMCH, China)扫描RAGE基因的启动子区，发现一个CpG岛(图1)。</p><p>图1. RAGE基因启动子区CpG岛示意图</p><p>首先利用亚硫酸氢盐测序法(Bisulfite sequencing PCR, BSP)技术分别在5例UC样本以及5例健康对照样本中检测该CpG岛上所有CpG位点的甲基化情况，BSP扩增使用下列引物序列，正向引物： 5'GGGATATGATTTTTGGATAGAGG3'，反向引物：5'CCAATCAATAATTCCCTAAAATAAC3'。BSP扩增长度为189 bp，产物包含9个CpG位点。扩增产物经过胶回收纯化之后连接PMD-20T质粒载体，转化DH5α大肠杆菌感受态细胞。细菌扩大培养后提取质粒利用3730XL (ABI, US)测序确定序列信息。</p><p>利用甲基化特异性PCR (Methylation-specific PCR, MSP)验证BSP结果并检测所有样本RAGE基因启动子区的甲基化情况。我们总共使用三对MSP引物，1对用于扩增甲基化的DNA序列(M-RAGE)；1对用于扩增未甲基化的DNA序列(U-RAGE)；最后1对引物作为对照扩增未经亚硫酸盐处理过的DNA模板，同时检测亚硫酸盐处理DNA模板的效果。所有本研究使用的引物序列信息都列在表1中。利用10%聚丙烯酰胺凝胶电泳分析MSP的产物，电泳结果由两位不知晓实验设计的实验人员分别读取电泳条带结果数据，记录相互印证的结果。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> MSP primer information used in this stud</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >引物</th><th align="center" valign="middle" >产物长度 size</th><th align="center" valign="middle" >引物长度(bp) bp</th><th align="center" valign="middle" >Tm (˚C)</th><th align="center" valign="middle" >“C”s</th><th align="center" valign="middle" >引物序列</th></tr></thead><tr><td align="center" valign="middle" >F-N-RAGE</td><td align="center" valign="middle"  rowspan="2"  >106</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >59</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >CCCCATGCATCCCCACCCCCGC</td></tr><tr><td align="center" valign="middle" >R-N-RAGE</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >ATCTGAGTCAGACACTCTCGTC</td></tr><tr><td align="center" valign="middle" >F-M-RAGE</td><td align="center" valign="middle"  rowspan="2"  >112</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >CGTTTTTATGTATTTTTATTTTCGT</td></tr><tr><td align="center" valign="middle" >R-M-RAGE</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >AATATCTAAATCAAACACTCTCGTC</td></tr><tr><td align="center" valign="middle" >F-U-RAGE</td><td align="center" valign="middle"  rowspan="2"  >112</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >TGTTTTTATGTATTTTTATTTTTGT</td></tr><tr><td align="center" valign="middle" >R-U-RAGE</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >AATATCTAAATCAAACACTCTCATC</td></tr></tbody></table></table-wrap><p>表1. 本研究使用的MSP引物信息</p><p>mRNA提取与荧光定量PCR</p><p>从结肠组织中提取总RNA并利用反转录试剂盒(TaKaRa, Dalian, China)反转录成cDNA。然后利用荧光定量PCR (QPCR)检测RAGE基因的mRNA转录水平，使用GAPDH作为内标。按照以下方式统计mRNA转录水平的平均值，实验分组包括启动子甲基化健康对照组，启动子非甲基化健康对照组，启动子甲基化UC组和启动子非甲基化UC组。统计分析每组间的mRNA水平的差异性。</p></sec><sec id="s5"><title>3. 结果与分析</title><p>亚硫酸氢盐测序PCR</p><p>利用MethPrimer (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi)在线软件发现RAGE启动子区包括一个124 bp的CpG岛，该区域包含9个CpG位点(图1)。BSP引物扩增产物长度为189 bp，覆盖整个CpG岛(图1)。扩增产物经过胶回收后装载进包含氨苄青霉素抗性的质粒载体并转化感受态细胞，经过青霉素抗性筛选培养挑选单菌落接种于液体培养基培养。富集菌体提取质粒后利用ABI 3730XL进行sanger测序。每个样本选取5个克隆测序，测序结果显示健康对照样本扩增区域的甲基化程度明显高于UC样本(图2)。</p><p>图2. BSP检测RAGE启动子区甲基化情况</p><p>甲基化特异性的PCR</p><p>利用聚丙烯酰胺凝胶电泳(PAGE)检测甲基化特异性PCR引物扩增产物。N-RAGE引物扩增非亚硫酸盐处理的DNA模板后PCR产物能够在凝胶上呈现清晰的阳性条带(图3(a))；N-RAGE引物扩增亚硫酸盐处理的DNA模板的产物在凝胶上则没有明显的条带出现(图3(c))。这证明亚硫酸盐处理DNA比较彻底，非甲基化胞嘧啶已经被转化成尿嘧啶导致N-RAGE引物不能有效扩增。</p><p>图3. PAGE检测MSP扩增RAGE基因启动子区产物结果</p><p>同样利用PAGE检测M-RAGE引物扩增亚硫酸盐处理过的DNA模板后PCR产物，发现多数对照样本在凝胶上出现明显条带而UC患者样本基本没有明显条带(图3(b))；反之，PAGE检测U-RAGE引物扩增亚硫酸盐处理过的DNA模板后PCR产物，UC患者样本中出现清晰的扩增条带，而对照样本则没有明显条带出现(图3(d))。统计所有样本的甲基化情况并分析与UC风险的相关性，结果如表2所示。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Analysis of correlation between RAGE promoter methylation and U</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >对照(%)</th><th align="center" valign="middle" >UC (%)</th><th align="center" valign="middle" >OR (95% CI)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >M+</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >19</td><td align="center" valign="middle"  rowspan="2"  >-</td><td align="center" valign="middle"  rowspan="2"  >-</td></tr><tr><td align="center" valign="middle" >64.8%</td><td align="center" valign="middle" >35.2%</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >M−</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >41</td><td align="center" valign="middle"  rowspan="2"  >0.305 (0.143~0.649)</td><td align="center" valign="middle"  rowspan="2"  >0.003</td></tr><tr><td align="center" valign="middle" >35.9%</td><td align="center" valign="middle" >64.1%</td></tr></tbody></table></table-wrap><p>表2. RAGE启动子甲基化与UC相关性分析</p><p>M+表示MSP检测启动子区有甲基化，M−表示MSP检测启动子区无甲基化。</p><p>RAGE基因转录水平</p><p>利用QPCR检测RAGE基因mRNA水平，分析数据发现启动子区非甲基化个体的平均mRNA转录水平高于甲基化个体。尤其是在UC患者群体中，启动子区非甲基化个体RAGE基因的mRNA水平显著高于其他各组(p &lt; 0.001) (图4)。</p></sec><sec id="s6"><title>4. 分析与讨论</title><p>越来越多的研究发现DNA甲基化和UC发病具有密切相关性 [<xref ref-type="bibr" rid="hanspub.28637-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.28637-ref27">27</xref>] 。Lin等人于2012年报道在B细胞中发现11个IBD相关的CpG位点，14个CD特异性相关的CpG位点以及24个UC特异性相关的CpG位点。这些位点分布于多个与免疫炎症相关的基因上 [<xref ref-type="bibr" rid="hanspub.28637-ref16">16</xref>] 。虽然众多研究表明RAGE基因在免疫和炎症反应过程具有重要作用，但是鲜有文献报道RAGE基因甲基化与UC风险的关系。</p><p>图4. 不同分组中RAGE基因mRNA水平</p><p>Hudson等人报道位于RAGE基因启动子区的多态性位点−374A/T (rs1800624)可引起3倍的转录活性 [<xref ref-type="bibr" rid="hanspub.28637-ref28">28</xref>] 。D&#228;britz也报道RAGE基因启动子区rs1800624多态性位点促进其转录并影响CD的发展 [<xref ref-type="bibr" rid="hanspub.28637-ref29">29</xref>] 。Wang等人也发现rs1800624位点与CD风险密切相关 [<xref ref-type="bibr" rid="hanspub.28637-ref30">30</xref>] 。然而，我们之前在中国人群中研究RAGE多态性位点与UC风险，数据表明编码区的多态性位点G82S与中国人群UC风险密切相关，但是启动子区的两个多态性位点与UC风险没有显著相关性 [<xref ref-type="bibr" rid="hanspub.28637-ref25">25</xref>] ；因此我们认为可能存在另外的因素影响RAGE的转录过程。大多数研究发现启动子区甲基化可能会抑制基因的转录水平，本研究发现健康对照人群中RAGE基因启动子区甲基化比例显著高于UC患者。同时，启动子区甲基化个体的RAGE基因平均mRNA转录水平显著低于非甲基化个体的平均mRNA转录水平。这说明我们发现的RAGE基因启动子区CpG岛的甲基化水平可能影响其转录过程，从而影响RAGE介导的炎症反应最终影响UC风险。</p><p>本研究利用MSP检测RAGE基因启动子区甲基化情况，PAGE凝胶上出现清晰的电泳条带则判定为阳性结果，没有电泳条带判定为阴性结果。该方法虽然简洁但因为PAGE的分辨率等问题存在一定的局限性；采用更精确的甲基化检测方法(例如焦磷酸测序等)可能会获得更加精确的数据结果。此外我们采用的样本量比较小并且全部样本均来自中国南方人群，种群组成单一，不排除有地域性环境因素影响结果。因此，本研究的结论需要更多不同种族群体的更多样本的验证。此外，本研究虽然发现RAGE基因启动子区甲基化与其转录调控密切相关，但不能确定启动子区多态性位点是不是同时参与RAGE基因转录调控过程。因此非常有必要在更多种族更大群体中同时研究RAGE基因启动子区多态性位点与甲基化对其转录过程的调控作用。</p></sec><sec id="s7"><title>5. 结论</title><p>我们第一次在中国人群中发现RAGE启动子区一个CpG岛甲基化水平与其转录水平密切相关，并可能成为临床UC风险检测的生物标志物，为UC风险的诊断治疗提供更多的理论依据。</p></sec><sec id="s8"><title>基金项目</title><p>本研究受到以下项目资助：国家自然科学基金(81600445)，广东省医学科研基金(No. A2016522)，广东医科大学科研基金(Z2014006，M2017009)，广东医科大学附属医院博士基金(528B20150012)。</p></sec><sec id="s9"><title>文章引用</title><p>周玉兰,闫守泉,蔡月清,苏振演,王家丰. 启动子甲基化通过调节RAGE基因表达影响UC风险Promoter Methylation Alters the UC Risk by Regulating RAGE Expression[J]. 临床医学进展, 2019, 09(01): 88-95. https://doi.org/10.12677/ACM.2019.91015</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28637-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cho, J.H. (2008) The Genetics and Immunopathogenesis of Inflammatory Bowel Disease. Nature Reviews Immunology, 8, 458-466. &lt;br&gt;https://doi.org/10.1038/nri2340</mixed-citation></ref><ref id="hanspub.28637-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gyde, S.N., Prior, P., Allan, R.N., et al. (1988) Colorectal Cancer in Ulcerative Colitis: A Cohort Study of Primary Referrals from Three Centres. Gut, 29, 206-217. &lt;br&gt;https://doi.org/10.1136/gut.29.2.206</mixed-citation></ref><ref id="hanspub.28637-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Isbell, G. and Levin, B. (1988) Ulcerative Colitis and Colon Cancer. Gastroenterology Clinics of North America, 17, 773-791.</mixed-citation></ref><ref id="hanspub.28637-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ekbom, A., Helmick, C., Zack, M., et al. (1990) Ulcer-ative Colitis and Colorectal Cancer. A Population-Based Study. The New England Journal of Medicine, 323, 1228-1233. &lt;br&gt;https://doi.org/10.1056/NEJM199011013231802</mixed-citation></ref><ref id="hanspub.28637-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Pia, A., Rainer, P., Michael, G., et al. (2002) Epigenetic Control of the E-Cadherin Gene (CDH1) by CpG Methylation in Colectomy Samples of Patients with Ulcerative Colitis. Genes Chromosomes &amp; Cancer, 35, 121-126.  
&lt;br&gt;https://doi.org/10.1002/gcc.10101</mixed-citation></ref><ref id="hanspub.28637-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hofmann, M.A., Drury, S., Fu, C., et al. (1999) RAGE Mediates a Novel Proinflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides. Cell, 97, 889-901. &lt;br&gt;https://doi.org/10.1016/S0092-8674(00)80801-6</mixed-citation></ref><ref id="hanspub.28637-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sparvero, L.J., Asafu-Adjei, D., Rui, K., et al. (2009) RAGE (Receptor for Advanced GlycationEndproducts), RAGE Ligands, and Their Role in Cancer and Inflammation. Journal of Translational Medicine, 7, 17.  
&lt;br&gt;https://doi.org/10.1186/1479-5876-7-17</mixed-citation></ref><ref id="hanspub.28637-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lutterloh, E.C., Opal, S.M., Pittman, D.D., et al. (2007) Inhibition of the RAGE Products Increases Survival in Experimental Models of Severe Sepsis and Systemic Infection. Critical Care, 11, R122. &lt;br&gt;https://doi.org/10.1186/cc6184</mixed-citation></ref><ref id="hanspub.28637-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">van Zoelen, M.A., Schmidt, A.M., Florquin, S., et al. (2009) Receptor for Advanced Glycation End Products Facilitates Host Defense during Escherichia coli-Induced Abdominal Sepsis in Mice. The Journal of Infectious Diseases, 200, 765-773. &lt;br&gt;https://doi.org/10.1086/604730</mixed-citation></ref><ref id="hanspub.28637-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chavakis, T., Bierhaus, A., Al-Fakhri, N., et al. (2003) The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leu-kocyte Integrins: A Novel Pathway for Inflammatory Cell Recruitment. Journal of Experimental Medicine, 198, 1507-1515. &lt;br&gt;https://doi.org/10.1084/jem.20030800</mixed-citation></ref><ref id="hanspub.28637-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Shi, F.Y., Ramasamy, R. and Schmidt, A.M. (2009) Re-ceptor for AGE (RAGE) &amp; Its Ligands—Cast into Leading Roles in Diabetes &amp; the Inflammatory Response. Journal of Molecular Medicine, 87, 235-247.  
&lt;br&gt;https://doi.org/10.1007/s00109-009-0439-2</mixed-citation></ref><ref id="hanspub.28637-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zen, K., Chen, C.X., Chen, Y.T., et al. (2007) Receptor for Ad-vanced Glycationendproducts Mediates Neutrophil Migration across Intestinal Epithelium. Journal of Immunology, 178, 2483-2490.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.178.4.2483</mixed-citation></ref><ref id="hanspub.28637-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Geetha, S., Jonamani, N., Bernd, W., et al. (2010) Carboxylated N-Glycans on RAGE Promote S100A12 Binding and Signaling. Journal of Cellular Biochemistry, 110, 645-659. &lt;br&gt;https://doi.org/10.1002/jcb.22575</mixed-citation></ref><ref id="hanspub.28637-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jones, P.A. and Laird, P.W. (1999) Cancer-Epigenetics Comes of Age. Nature Genetics, 21, 163.  
&lt;br&gt;https://doi.org/10.1038/5947</mixed-citation></ref><ref id="hanspub.28637-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Arisawa, T., Tahara, T., Shibata, T., et al. (2007) Promoter Hypomethylation of Protease-Activated Receptor 2 Associated with Carcinogenesis in the Stomach. Journal of Gastroenterology &amp; Hepa-tology, 22, 943-948.  
&lt;br&gt;https://doi.org/10.1111/j.1440-1746.2007.04847.x</mixed-citation></ref><ref id="hanspub.28637-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Z., Hegarty, J.P., Yu, W., et al. (2012) Identification of Disease-Associated DNA Methylation in B Cells from Crohn’s Disease and Ulcerative Colitis Patients. Digestive Diseases &amp; Sciences, 57, 3145-3153.  
&lt;br&gt;https://doi.org/10.1007/s10620-012-2288-z</mixed-citation></ref><ref id="hanspub.28637-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Saito, S., Kato, J., Hiraoka, S., et al. (2011) DNA Methylation of Colon Mucosa in Ulcerative Colitis Patients: Correlation with Inflammatory Status. Inflammatory Bowel Diseases, 17, 1955-1965. &lt;br&gt;https://doi.org/10.1002/ibd.21573</mixed-citation></ref><ref id="hanspub.28637-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Herman, J.G. and Baylin, S.B. (2003) Gene Silencing in Cancer in Association with Promoter Hypermethylation. New England Journal of Medicine, 349, 2042-2054. &lt;br&gt;https://doi.org/10.1056/NEJMra023075</mixed-citation></ref><ref id="hanspub.28637-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Feinberg, A.P. and Tycko, B. (2004) The History of Cancer Epige-netics. Nature Reviews Cancer, 4, 143-153.  
&lt;br&gt;https://doi.org/10.1038/nrc1279</mixed-citation></ref><ref id="hanspub.28637-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Gunnar, E. and Nils, W. (2004) Epigenetics in Human Disease and Prospects for Epigenetic Therapy. Nature, 429, 457-463. &lt;br&gt;https://doi.org/10.1038/nature02625</mixed-citation></ref><ref id="hanspub.28637-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Esteller, M. (2005) Aberrant DNA Methylation as a Cancer-Inducing Mechanism. Annual Review of Pharmacology &amp; Toxicology, 45, 629-656. &lt;br&gt;https://doi.org/10.1146/annurev.pharmtox.45.120403.095832</mixed-citation></ref><ref id="hanspub.28637-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Baylin, S.B., Herman, J.G., Graff, J.R., et al. (1998) Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia. Advances in Cancer Research, 72, 141-196. &lt;br&gt;https://doi.org/10.1016/S0065-230X(08)60702-2</mixed-citation></ref><ref id="hanspub.28637-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kanai, Y. (2010) Genome-Wide DNA Methylation Profiles in Precancerous Conditions and Cancers. Cancer Science, 101, 36-45. &lt;br&gt;https://doi.org/10.1111/j.1349-7006.2009.01383.x</mixed-citation></ref><ref id="hanspub.28637-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Garritypark, M.M., Loftus, E.V.J., Sandborn, W.J., et al. (2010) Methylation Status of Genes in Non-Neoplastic Mucosa from Patients with Ulcerative Colitis-Associated Colo-rectal Cancer. American Journal of Gastroenterology, 105, 1610-1619. &lt;br&gt;https://doi.org/10.1038/ajg.2010.22</mixed-citation></ref><ref id="hanspub.28637-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Zeng, J., Wang, H., et al. (2016) Genetic Polymorphisms of RAGE and Risk of Ulcerative Colitis in a Chinese Population. Immunology Letters, 170, 88-94. &lt;br&gt;https://doi.org/10.1016/j.imlet.2015.09.003</mixed-citation></ref><ref id="hanspub.28637-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Tahara, T., Shibata, T., Nakamura, M., et al. (2009) Effect of MDR1 Gene Promoter Methylation in Patients with Ulcerative Colitis. International Journal of Molecular Medicine, 23, 521-527. &lt;br&gt;https://doi.org/10.3892/ijmm_00000160</mixed-citation></ref><ref id="hanspub.28637-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Tahara, T., Shibata, T., Nakamura, M., et al. (2009) Promoter Methylation of Protease-Activated Receptor (PAR2) Is Associated with Severe Clinical Phenotypes of Ul-cerative Colitis (UC). Clinical and Experimental Medicine, 9, 125-130. &lt;br&gt;https://doi.org/10.1007/s10238-008-0025-x</mixed-citation></ref><ref id="hanspub.28637-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Hudson, B.I., Stickland, M.H., Futers, T.S., et al. (2001) Effects of Novel Polymorphisms in the RAGE Gene on Transcriptional Regulation and Their Association with Diabetic Reti-nopathy. Diabetes, 50, 1505-1511.  
&lt;br&gt;https://doi.org/10.2337/diabetes.50.6.1505</mixed-citation></ref><ref id="hanspub.28637-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Däbritz, J., Friedrichs, F., Weinhage, T., et al. (2011) The Func-tional-374T/A Polymorphism of the Receptor for Advanced Glycation End Products May Modulate Crohn’s Disease. Gastroenterology, 300, G823-G832.</mixed-citation></ref><ref id="hanspub.28637-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z.T., Hu, J.J., Fan, R., et al. (2014) RAGE Gene Three Polymor-phisms with Crohn’s Disease Susceptibility in Chinese Han Population. World Journal of Gastroenterology, 20, 2397. &lt;br&gt;https://doi.org/10.3748/wjg.v20.i9.2397</mixed-citation></ref></ref-list></back></article>